Effects of an Antiestrogen and Estradiol on Food Intake, Body Composition, and Metabolism in Ovariectomized Rats
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Wo 2009/082437 A9
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 2 July 2009 (02.07.2009) WO 2009/082437 A9 (51) International Patent Classification: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, C07D 207/08 (2006.01) A61K 31/402 (2006.01) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, C07D 207/09 (2006.01) A61P 5/26 (2006.01) NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, C07D 498/04 (2006.01) SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (21) International Application Number: PCT/US2008/013657 (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (22) International Filing Date: G M M N S D S L s z τ z U G Z M 12 December 2008 (12.12.2008) z w Eurasian (A M B γ KG> M D RU> τ (25) Filing Language: English TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (26) Publication Language: English M C M T N L N O P L P T R O S E S I s T R OAPI (30) Priority Data: B F ' B J ' C F ' C G ' C I' C M ' G A ' G N ' 0 G W ' M L ' M R ' 61/008,731 2 1 December 2007 (21 .12.2007) US N E ' S N ' T D ' T G ) - (71) Applicant (for all designated States except US): LIG- Declarations under Rule 4.17: AND PHARMACEUTICALS INCORPORATED [US/ — as to applicant's entitlement to apply for and be granted US]; 11085 N. -
The Effects of Androgens and Antiandrogens on Hormone Responsive Human Breast Cancer in Long-Term Tissue Culture1
[CANCER RESEARCH 36, 4610-4618, December 1976] The Effects of Androgens and Antiandrogens on Hormone responsive Human Breast Cancer in Long-Term Tissue Culture1 Marc Lippman, Gail Bolan, and Karen Huff MedicineBranch,NationalCancerInstitute,Bethesda,Maryland20014 SUMMARY Information characterizing the interaction between an drogens and breast cancer would be desirable for several We have examined five human breast cancer call lines in reasons. First, androgens can affect the growth of breast conhinuous tissue culture for andmogan responsiveness. cancer in animals. Pharmacological administration of an One of these cell lines shows a 2- ho 4-fold stimulation of drogens to rats bearing dimathylbenzanthracene-induced thymidina incorporation into DNA, apparent as early as 10 mammary carcinomas is associated wihh objective humor hr following androgen addition to cells incubated in serum regression (h9, 22). Shionogi h15 cells, from a mouse mam free medium. This stimulation is accompanied by an ac many cancer in conhinuous hissue culture, have bean shown celemation in cell replication. Antiandrogens [cyproterona to be shimulatedby physiological concentrations of andro acetate (6-chloro-17a-acelata-1,2a-methylena-4,6-pregna gen (21), thus suggesting that some breast cancer might be diene-3,20-dione) and R2956 (17f3-hydroxy-2,2,1 7a-tnima androgen responsive in addition to being estrogen respon thoxyastra-4,9,1 1-Inane-i -one)] inhibit both protein and siva. DNA synthesis below control levels and block androgen Evidence also indicates that tumor growth in humans may mediahed stimulation. Prolonged incubahion (greahenhhan be significantly altered by androgens. About 20% of pahianhs 72 hn) in antiandrogen is lethal. -
Alpha-Fetoprotein: the Major High-Affinity Estrogen Binder in Rat
Proc. Natl. Acad. Sci. USA Vol. 73, No. 5, pp. 1452-1456, May 1976 Biochemistry Alpha-fetoprotein: The major high-affinity estrogen binder in rat uterine cytosols (rat alpha-fetoprotein/estrogen receptors) JOSE URIEL, DANIELLE BOUILLON, CLAUDE AUSSEL, AND MICHELLE DUPIERS Institut de Recherches Scientifiques sur le Cancer, Boite Postale No. 8, 94800 Villejuif, France Communicated by Frangois Jacob, February 3, 1976 ABSTRACT Evidence is presented that alpha-fetoprotein nates in hypotonic solutions, whereas in salt concentrations (AFP), a serum globulin, accounts mainly, if not entirely, for above 0.2 M the 4S complex is by far the major binding enti- the high estrogen-binding properties of uterine cytosols from immature rats. By the use of specific immunoadsorbents to ty. AFP and by competitive assays with unlabeled steroids and The relatively high levels of serum AFP in immature rats pure AFP, it has been demonstrated that in hypotonic cyto- prompted us to explore the contribution of AFP to the estro- sols AFP is present partly as free protein with a sedimenta- gen-binding capacity of uterine homogenates. The results tion coefficient of about 4-5 S and partly in association with obtained with specific anti-AFP immunoadsorbents (12, 13) some intracellular constituent(s) to form an 8S estrogen-bind- provided evidence that at low salt concentrations,'AFP ac-' ing entity. The AFP - 8S transformation results in a loss of antigenic reactivity to antibodies against AFP and a signifi- counts for most of the estrogen-binding capacity associated cant change in binding specificity. This change in binding with the 4-5S macromolecular complex. -
Failures and Controversies of the Antiestrogen Treatment of Breast Cancer
In: Estrogen Prevention for Breast Cancer ISBN: 978-1-62417-378-3 Editor: Zsuzsanna Suba © 2013 Nova Science Publishers, Inc. No part of this digital document may be reproduced, stored in a retrieval system or transmitted commercially in any form or by any means. The publisher has taken reasonable care in the preparation of this digital document, but makes no expressed or implied warranty of any kind and assumes no responsibility for any errors or omissions. No liability is assumed for incidental or consequential damages in connection with or arising out of information contained herein. This digital document is sold with the clear understanding that the publisher is not engaged in rendering legal, medical or any other professional services. Chapter VII Failures and Controversies of the Antiestrogen Treatment of Breast Cancer Zsuzsanna Suba National Institute of Oncology, Department of Surgical and Molecular Pathology, Budapest, Hungary Abstract In postmenopausal women, estrogens have unquestionable preventive and curative effects against atherogenic cardiovascular lesions, osteoporosis and neurodegenerative diseases. Moreover, recent studies on correlations between hormone replacement therapy and cancer risk could justify preventive, anticancer capacities of estrogen both on smoking associated and hormone related cancers. Experimental developing of antiestrogen compounds aimed to inhibit the binding of presumably harmful, endogenous estrogen to its receptor system so as to achieve a regression of hormone-related cancers. However, antiestrogens proved to be ineffective in the majority of selected receptor positive breast cancer cases and produced severe side effects, such as vascular complications and cancer development at several sites. Failure of antiestrogen therapy was designated as ―endocrine resistance‖ of tumors. -
NDA/BLA Multi-Disciplinary Review and Evaluation
NDA/BLA Multi-disciplinary Review and Evaluation NDA 214154 Nextstellis (drospirenone and estetrol tablets) NDA/BLA Multi-Disciplinary Review and Evaluation Application Type NDA Application Number(s) NDA 214154 (IND 110682) Priority or Standard Standard Submit Date(s) April 15, 2020 Received Date(s) April 15, 2020 PDUFA Goal Date April 15, 2021 Division/Office Division of Urology, Obstetrics, and Gynecology (DUOG) / Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine (ORPURM) Review Completion Date April 15, 2021 Established/Proper Name drospirenone and estetrol tablets (Proposed) Trade Name Nextstellis Pharmacologic Class Combination hormonal contraceptive Applicant Mayne Pharma LLC Dosage form Tablet Applicant proposed Dosing x Take one tablet by mouth at the same time every day. Regimen x Take tablets in the order directed on the blister pack. Applicant Proposed For use by females of reproductive potential to prevent Indication(s)/Population(s) pregnancy Recommendation on Approval Regulatory Action Recommended For use by females of reproductive potential to prevent Indication(s)/Population(s) pregnancy (if applicable) Recommended Dosing x Take one pink tablet (drospirenone 3 mg, estetrol Regimen anhydrous 14.2 mg) by mouth at the same time every day for 24 days x Take one white inert tablet (placebo) by mouth at the same time every day for 4 days following the pink tablets x Take tablets in the order directed on the blister pack 1 Reference ID: 4778993 NDA/BLA Multi-disciplinary Review and Evaluation NDA 214154 Nextstellis (drospirenone and estetrol tablets) Table of Contents Table of Tables .................................................................................................................... 5 Table of Figures ................................................................................................................... 7 Reviewers of Multi-Disciplinary Review and Evaluation ................................................... -
Synthesis of Lasofoxifene, Nafoxidine and Their Positional Isomers Via the Novel Three-Component Coupling Reaction
Molecules 2010, 15, 6773-6794; doi:10.3390/molecules15106773 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Article Synthesis of Lasofoxifene, Nafoxidine and Their Positional Isomers via the Novel Three-Component Coupling Reaction Kenya Nakata, Yoshiyuki Sano and Isamu Shiina * Department of Applied Chemistry, Faculty of Science, Tokyo University of Science, 1-3 Kagurazaka, Shinjuku-ku, Tokyo 162-8601, Japan * Author to whom correspondence should be addressed; E-Mail: [email protected]; Fax: +81-3-3260-5609. Received: 21 August 2010; in revised form: 13 September 2010 / Accepted: 20 September 2010/ Published: 28 September 2010 Abstract: A Lewis acid-mediated three-component coupling reaction was successfully applied for the synthesis of lasofoxifene (1), nafoxidine (2), and their positional isomers, inv-lasofoxifene (3) and inv-nafoxidine (4). In the presence of HfCl4, the desired one-pot coupling reaction among 4-pivaloyloxybenzaldehyde (5), cinnamyltrimethylsilane (6), and anisole proceeded to afford the corresponding 3,4,4-triaryl-1-butene 7 in high yield. The iodocarbocyclization of the coupling product and the successive elimination of hydrogen iodide forming the olefin part, followed by the migration of the double-bond afforded the common synthetic intermediate of lasofoxifene (1) and nafoxidine (2) via a very concise procedure. Additionally, the syntheses of their positional isomers inv-lasofoxifene (3) and inv-nafoxidine (4) were also achieved through very convenient protocols. Keywords: three-component coupling reaction; diversity oriented synthesis; lasofoxifene; nafoxidine; inv-lasofoxifene; inv-nafoxidine 1. Introduction Multi-component coupling reactions (MCRs) are one of the most important tools in organic synthesis for the divergent production of bioactive molecules and highly complicated natural products [1-3]. -
Topical Administration of Toremifene and Its
Patentamt |||| ||| 1 1|| ||| ||| ||| ||| || || || ||| |||| || JEuropaischesJ European Patent Office Office europeen des brevets (11) EP 0 633 774 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) int. CI.6: A61 K 31/135, A61K9/70, of the grant of the patent: ^g-| ^ 47/48 17.02.1999 Bulletin 1999/07 (86) International application number: ..... - ......„,,„number: 93906654.4 , (21) Application PCT/FI93/001 1 9 (22) Date of filing: 25.03.1993 x ' 3 (87)/Q-,X International, , ,..... publication ,.. number: WO 93/19746 (14.10.1993 Gazette 1993/25) (54) TOPICAL ADMINISTRATION OF TOREMIFENE AND ITS METABOLITES TOPISCH ANWENDBARE ARZNEIMITTEL, ENTHALTEND TOREMIFEN UND DESSEN METABOLITE ADMINISTRATION TOPIQUE DE TOREMIFENE ET DE SES METABOLITES (84) Designated Contracting States: • KURKELA, Kauko Oiva Antero AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL 02180 Espoo (Fl) PTSE (74) Representative: (30) Priority: 03.04.1992 GB 9207437 Sexton, Jane Helen et al J.A. KEMP & CO. (43) Date of publication of application: 14 South Square 18.01.1995 Bulletin 1995/03 Gray's Inn London WC1 R 5LX (GB) (73) Proprietor: ORION-YHTYM A OY 02200 Espoo (Fl) (56) References cited: EP-A- 0 095 875 US-A- 4 990 538 (72) Inventors: • DEGREGORIO, Michael, William Granite Bay, CA 95746 (US) CO r»- r»- co CO Note: Within nine months from the publication of the mention of the grant of the European patent, give CO any person may notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in o a written reasoned statement. -
A Phosphotyrosyl Peptide That Blocks Dimerization of the Human Estrogen Receptor (Estradiol/MCF-7 Cells/Tyrosine Phosphorylation/Dimerization/DNA Binding) STEVEN F
Proc. Natl. Acad. Sci. USA Vol. 92, pp. 7475-7479, August 1995 Biochemistry An antiestrogen: A phosphotyrosyl peptide that blocks dimerization of the human estrogen receptor (estradiol/MCF-7 cells/tyrosine phosphorylation/dimerization/DNA binding) STEVEN F. ARNOLD AND ANGELO C. NOTIDES* Departments of Environmental Medicine and Biophysics, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642 Communicated by Jack Gorski, University of Wisconsin, Madison, WI, April 28, 1995 (received for review January 13, 1995) ABSTRACT We have previously identified tyrosine-537 scription (STAT) bind DNA as dimers through a reciprocal as a constitutively phosphorylated site on the human estrogen association of a phosphotyrosine on one monomer with a Src receptor (hER). A 12-amino acid phosphotyrosyl peptide homology 2 domain (SH2 domain) on the complementary containing a selected sequence surrounding tyrosine-537 was monomer (15, 16). used to investigate the function of phosphotyrosine-537. The Deletion and mutational analyses have provided evidence phosphotyrosyl peptide completely blocked the binding of the that the C terminus of the steroid hormone receptors is hER to an estrogen response element (ERE) in a gel mobility necessary for receptor dimerization (4). The dimerization of shift assay. Neither the nonphosphorylated tyrosyl peptide the nuclear hormone receptors is reported to be regulated by nor an unrelated phosphotyrosyl peptide previously shown to hydrophobic heptad repeats in the C terminus (17, 18). A inhibit the signal transducers and activators of transcription 22-amino acid sequence from positions 501 to 522 in the C factor (STAT) blocked binding of the hER to the ERE. The terminus of the mouse estrogen receptor was isolated that hER phosphotyrosyl peptide was shown by molecular sizing conferred DNA binding to DNA-binding-deficient mutants chromatography to dissociate the hER dimer into monomers. -
In Vitro and in Silico Analyses of the Inhibition of Human Aldehyde Oxidase By
JPET Fast Forward. Published on July 9, 2019 as DOI: 10.1124/jpet.119.259267 This article has not been copyedited and formatted. The final version may differ from this version. JPET #259267 In Vitro and In Silico Analyses of the Inhibition of Human Aldehyde Oxidase by Bazedoxifene, Lasofoxifene, and Structural Analogues Shiyan Chen, Karl Austin-Muttitt, Linghua Harris Zhang, Jonathan G.L. Mullins, and Aik Jiang Lau Downloaded from Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore jpet.aspetjournals.org (S.C., A.J.L.); Institute of Life Science, Swansea University Medical School, United Kingdom (K.A-M, J.G.L.M.); NanoBioTec, LLC., Whippany, New Jersey, U.S.A. (L.H.Z.); at ASPET Journals on September 29, 2021 Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (A.J.L.) 1 JPET Fast Forward. Published on July 9, 2019 as DOI: 10.1124/jpet.119.259267 This article has not been copyedited and formatted. The final version may differ from this version. JPET #259267 Running Title In Vitro and In Silico Analyses of AOX Inhibition by SERMs Corresponding author: Dr. Aik Jiang Lau Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore 117543. Downloaded from Tel.: 65-6601 3470, Fax: 65-6779 1554; E-mail: [email protected] jpet.aspetjournals.org Number of text pages: 35 Number of tables: 4 Number of figures: 8 at ASPET Journals on September 29, 2021 Number of references 60 Number of words in Abstract (maximum -
Use of Aromatase Inhibitors in Breast Carcinoma
Endocrine-Related Cancer (1999) 6 75-92 Use of aromatase inhibitors in breast carcinoma R J Santen and H A Harvey1 Department of Medicine, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA 1Department of Medicine, Penn State College of Medicine, Hershey, Pennsylvania 17033, USA (Requests for offprints should be addressed to R J Santen) Abstract Aromatase, a cytochrome P-450 enzyme that catalyzes the conversion of androgens to estrogens, is the major mechanism of estrogen synthesis in the post-menopausal woman. We review some of the recent scientific advances which shed light on the biologic significance, physiology, expression and regulation of aromatase in breast tissue. Inhibition of aromatase, the terminal step in estrogen biosynthesis, provides a way of treating hormone-dependent breast cancer in older patients. Aminoglutethimide was the first widely used aromatase inhibitor but had several clinical drawbacks. Newer agents are considerably more selective, more potent, less toxic and easier to use in the clinical setting. This article reviews the clinical data supporting the use of the potent, oral competitive aromatase inhibitors anastrozole, letrozole and vorozole and the irreversible inhibitors 4-OH andro- stenedione and exemestane. The more potent compounds inhibit both peripheral and intra-tumoral aromatase. We discuss the evidence supporting the notion that aromatase inhibitors lack cross- resistance with antiestrogens and suggest that the newer, more potent compounds may have a particular application in breast cancer treatment in a setting of adaptive hypersensitivity to estrogens. Currently available aromatase inhibitors are safe and effective in the management of hormone- dependent breast cancer in post-menopausal women failing antiestrogen therapy and should now be used before progestational agents. -
Kinetic Analysis of Estrogen Receptor Ligand Interactions
Kinetic analysis of estrogen receptor͞ ligand interactions Rebecca L. Rich*, Lise R. Hoth†, Kieran F. Geoghegan†, Thomas A. Brown†, Peter K. LeMotte†, Samuel P. Simons†, Preston Hensley†, and David G. Myszka*‡ *Center for Biomolecular Interaction Analysis, University of Utah, Salt Lake City, UT 84132; and †Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 Communicated by Pamela J. Bjorkman, California Institute of Technology, Pasadena, CA, May 14, 2002 (received for review February 18, 2002) Surface plasmon resonance biosensor technology was used to receptor͞ligand interactions. In a qualitative screening mode, directly measure the binding interactions of small molecules to the receptor binders and nonbinders were identified. In a quantita- ligand-binding domain of human estrogen receptor. In a screening tive high-resolution mode, precise kinetic and affinity parame- mode, specific ligands of the receptor were easily discerned from ters were obtained for compounds across a wide dynamic range. nonligands. In a high-resolution mode, the association and disso- These mechanistic data complement static structural informa- ciation phase binding responses were shown to be reproducible tion about ER (10–14), revealing how radically different rate and could be fit globally to a simple interaction model to extract constants govern the binding of agonist and selected antagonist reaction rate constants. On average, antagonist ligands (such as ligands. tamoxifen and nafoxidine) were observed to bind to the receptor with association rates that were 500-fold slower than agonists Methods (such as estriol and -estradiol). This finding is consistent with Reagents. Ligand-binding domains of human ER-␣ and - were these antagonists binding to an altered conformation of the expressed in Escherichia coli as His-tagged proteins and purified receptor. -
Network-Based Characterization of Drug-Protein Interaction Signatures
Tabei et al. BMC Systems Biology 2019, 13(Suppl 2):39 https://doi.org/10.1186/s12918-019-0691-1 RESEARCH Open Access Network-based characterization of drug-protein interaction signatures with a space-efficient approach Yasuo Tabei1*, Masaaki Kotera2, Ryusuke Sawada3 and Yoshihiro Yamanishi3,4 From The 17th Asia Pacific Bioinformatics Conference (APBC 2019) Wuhan, China. 14–16 January 2019 Abstract Background: Characterization of drug-protein interaction networks with biological features has recently become challenging in recent pharmaceutical science toward a better understanding of polypharmacology. Results: We present a novel method for systematic analyses of the underlying features characteristic of drug-protein interaction networks, which we call “drug-protein interaction signatures” from the integration of large-scale heterogeneous data of drugs and proteins. We develop a new efficient algorithm for extracting informative drug- protein interaction signatures from the integration of large-scale heterogeneous data of drugs and proteins, which is made possible by space-efficient representations for fingerprints of drug-protein pairs and sparsity-induced classifiers. Conclusions: Our method infers a set of drug-protein interaction signatures consisting of the associations between drug chemical substructures, adverse drug reactions, protein domains, biological pathways, and pathway modules. We argue the these signatures are biologically meaningful and useful for predicting unknown drug-protein interactions and are expected to contribute to rational drug design. Keywords: Drug-protein interaction prediction, Drug discovery, Large-scale prediction Background similar drugs are expected to interact with similar pro- Target proteins of drug molecules are classified into a pri- teins, with which the similarity of drugs and proteins are mary target and off-targets.